Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 6/2019

01-06-2019 | Kidney Cancer | Original Article

External validation of nomograms for prediction of progression-free survival and liver toxicity in patients with advanced renal cell carcinoma treated with pazopanib

Authors: Yasuyoshi Okamura, Nobuyuki Hinata, Tomoaki Terakawa, Junya Furukawa, Kenichi Harada, Yuzo Nakano, Ichiro Nakamura, Takaaki Inoue, Takayoshi Ogawa, Masato Fujisawa

Published in: International Journal of Clinical Oncology | Issue 6/2019

Login to get access

Abstract

Background

Nomograms have been developed for the prediction of progression-free survival (PFS) and liver toxicity in patients with advanced renal cell carcinoma (RCC) who are treated with pazopanib. The objectives of this study were to review clinical outcomes, to perform an external validation of these nomograms and to develop a new nomogram in Japanese patients.

Methods

A retrospective chart review of 150 Japanese patients with advanced RCC who received pazopanib at Kobe University Hospital and affiliated hospitals from March 2014 to June 2017 was performed. We evaluated the clinical efficacy and safety of pazopanib using logistic regression analysis to analyze the prognostic factors for overall survival (OS) and PFS. For nomogram validation, concordance index (C-index) and calibration were used.

Results

The median PFS and OS in this study was 13.1 and 37.4 months, respectively. Multivariate analyses identified prognostic factors for OS (number of metastasis, white blood cell (WBC) count and lactate dehydrogenase) and PFS (number of metastasis, WBC count). The C-index of nomograms for 12-month PFS was 0.598. The C-index of nomograms for liver toxicity was 0.558. A new Nomogram for predicting 12-month PFS for patients who received pazopanib was developed and performed internal validation. The C-index of the nomogram was 0.768.

Conclusion

The clinical effect and safety of pazopanib reported in this study was similar to previous studies. This study suggests careful application of nomograms to Japanese patients treated with pazopanib. We have developed a new nomogram for predicting 12-month PFS with pazopanib therapy from Japanese patients.
Literature
1.
Kane CJ, Mallin K, Ritchey J et al (2008) Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer 113:78–83CrossRefPubMed
2.
Kjaer M, Iversen P, Hvidt V et al (1987) A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group. Scand J Urol Nephrol 21(4):285–289CrossRefPubMed
3.
4.
5.
Motzer RJ, Bacik J, Murphy BA et al (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20(1):289–296CrossRefPubMed
6.
7.
8.
Heng DY, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27:5794–5799CrossRefPubMed
9.
Motzer RJ, Bukowski RM, Figlin RA et al (2008) Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 113:1552–1558CrossRefPubMed
10.
Kattan MW, Sternberg CN, Mehmud F et al (2015) Development and validation of a prognostic nomogram for progression-free survival in patients with advanced renal cell carcinoma treated with pazopanib. Oncology 89:235–241CrossRefPubMed
11.
Kattan MW, Winette TA, Powles T et al (2017) Development of a prognostic nomogram for liver toxicity in patients treated with pazopanib. J Clin Oncol 35:6_suppl 455–455CrossRef
12.
Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6):1061–1068CrossRefPubMed
13.
Motzer RJ, Hutson TE, McCann L et al (2014) Overall survival in renal cell carcinoma with pazopanib versus sunitinib. N Engl J Med 370(18):1769–1770CrossRefPubMed
14.
Tomita Y, Shinohara N, Yuasa T et al (2010) Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 40:1166–1172CrossRefPubMed
15.
Lee S, Bang Y, Mainwaring P et al (2014) Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy. Asia Pac J Clin Oncol 10(3):237–245CrossRefPubMed
16.
Choueiri TK, Garcia JA, Elson P et al (2007) Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110:543–550CrossRefPubMed
17.
Negrier S, Escudier B, Gomez F et al (2002) Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d’Immunotherapie. Ann Oncol 13:1460–1468CrossRefPubMed
18.
Manola J, Royston P, Elson P et al (2011) Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res 17:5443–5450CrossRefPubMedPubMedCentral
19.
Climent MA, Muñoz-Langa J, Basterretxea-Badiola L et al (2018) Systematic review and survival meta-analysis of real world evidence on first-line pazopanib for metastatic renal cell carcinoma. Crit Rev Oncol Hematol 121:45–50CrossRefPubMed
20.
Powles T, Bracarda S, Chen M et al (2015) Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients. Eur J Cancer 51(10):1293–1302CrossRefPubMed
21.
Yoo C, Kim JE, Lee JL et al (2010) The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn J Clin Oncol 40:980–985CrossRefPubMed
22.
Guo J, Jin J, Huang Y et al (2013) Comparison of PFS and safety for Asian compared to North American and European populations in the phase III trial of pazopanib versus sunitinib in patients with treatment-naive RCC (COMPARZ). J Clin Oncol 31(Suppl 6):Abstr 366CrossRef
Metadata
Title
External validation of nomograms for prediction of progression-free survival and liver toxicity in patients with advanced renal cell carcinoma treated with pazopanib
Authors
Yasuyoshi Okamura
Nobuyuki Hinata
Tomoaki Terakawa
Junya Furukawa
Kenichi Harada
Yuzo Nakano
Ichiro Nakamura
Takaaki Inoue
Takayoshi Ogawa
Masato Fujisawa
Publication date
01-06-2019
Publisher
Springer Singapore
Published in
International Journal of Clinical Oncology / Issue 6/2019
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-019-01401-5

Other articles of this Issue 6/2019

International Journal of Clinical Oncology 6/2019 Go to the issue

Review Article

Efficacy and safety of oxaliplatin-based regimen versus cisplatin-based regimen in the treatment of gastric cancer: a meta-analysis of randomized controlled trials

Original Article

Control of intracranial disease is associated with improved survival in patients with brain metastasis from hepatocellular carcinoma

Original Article

Optimal treatment strategy for rectal cancer based on the risk factors for recurrence patterns

Original Article

Pharmacokinetics of S-1 monotherapy in plasma and in tears for gastric cancer patients

Original Article

Diagnostic value of multimodal ultrasound imaging in differentiating benign and malignant TI-RADS category 4 nodules

Original Article

Radiotherapy alone as a possible de-intensified treatment for human papillomavirus-related locally advanced oropharyngeal squamous cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits